How Much Does Therapeutic Apheresis Cost in China?
| China | Turkey | Austria | |
|---|---|---|---|
| Therapeutic Apheresis | ≈ $900 | from $4,500 | ≈ $1,800 |
| Selective Apheresis | ≈ $3,500 | ≈ $1,200 | ≈ $1,800 |
| Plasmapheresis | ≈ $2,200 | from $3,200 | ≈ $1,500 |
| Plasma Exchange | from $6,000 | ≈ $1,800 | ≈ $3,800 |
| LDL Apheresis | ≈ $700 | ≈ $450 | ≈ $1,100 |
Your Benefits and Guarantees with Bookimed
Transparent Prices & Flexible Installments
No hidden fees – just official clinic prices. Pay at the clinic for Therapeutic Apheresis upon arrival and use a flexible installment plan if needed.
Verified Clinics & Doctors Only
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Therapeutic Apheresis and have the necessary licenses to serve international patients worldwide.
Free 24/7 Assistance
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Therapeutic Apheresis journey.

Your personal Bookimed medical coordinator
- Supports you at every stage
- Helps choose the right clinic and doctor
- Ensures quick and convenient access to information
Discover the Best Therapeutic Apheresis Clinics in China: 1 Verified Option and Prices
Therapeutic Apheresis Overview in China
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Doctors
View all Doctors
Liao Zhengyin
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Xiao Yueyong
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.

Zhang Yan Lin
National renowned authority in nephrology with 30+ years of experience. Prof. Zhang specializes in therapeutic apheresis at Xiamen Humanity Hospital.
- Deputy Chairperson of Immunoadsorption and Cell Therapy Group
- Participated in multiple National Natural Science Foundation projects
- Author of 30+ publications, including 6 SCl-indexed papers
- Expertise in renal replacement therapies including hemodialysis
- Standing Committee Member in multiple national nephrology associations

Xu Juntang
Dr. Xu Juntang, MD, is a Postdoctoral Fellow, Chief Physician, and Master’s Supervisor. He is the Director of Cardiovascular Medicine at Xiamen Humanity Hospital. His work focuses on preventing and treating cardiovascular and thrombotic diseases, including coronary artery disease, hypertension, heart failure, arrhythmias, and emergencies. He is skilled in cardiovascular biomarker testing.
He provides standardized care for thromboembolism related to valvular heart disease and non‑valvular atrial fibrillation, pulmonary embolism, deep vein thrombosis, and obstetric thrombophilia. He also conducts clinical and laboratory assessments of thrombosis and coagulation disorders. He is the Vice Chairman of the Laboratory and Clinical Branch of the Chinese Society of Cardiothoracic and Vascular Anesthesiology.
Video Stories from Bookimed Patients
Share this content
Anna Leonova

